Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626024 · ClinicalTrials.gov registry record · Phase 2
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
A Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT04626024 is a Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 100 participants, below the 207-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (52% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT04626024, a Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Conditions Studied
Interventions
- OTHER Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- DRUG Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Study Locations (4)
Texas
- Baylor College of Medicine- McNair Campus - Houston
- Ben Taub General Hospital - Houston
- CHI St. Luke's Health Baylor College of Medicine Medical Center - Houston
- Harris Health System- Smith Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04626024
The ClinicalTrials.gov registry entry for NCT04626024 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (52% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal is the first listed.
NCT04626024 reports 4 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04626024 about?
NCT04626024 is a clinical study titled "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population". This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
What is the current status of trial NCT04626024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-12-22. Estimated completion is 2028-11-15.
What conditions does trial NCT04626024 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission.
What interventions are being tested in trial NCT04626024?
The interventions under investigation include: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal (OTHER), Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation (DRUG).
Who is sponsoring clinical trial NCT04626024?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04626024 being conducted?
This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
COMPLETED · Phase 2
-
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
COMPLETED · Phase 2
Explore more on PlainTrial
Chronic Myeloid Leukemia
All registered trials for this condition
Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.